SCHEMBL1660876

SCHEMBL1660876

CC(N)(CC(=O)O)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.55
CYP2C19 P33261 2/20 0.55
HIF1A Q16665 2/20 0.55
CYP2D6 P10635 1/20 0.55
ADRA1A P35348 2/20 0.50
HMGCR P04035 1/20 0.50
CHRM1 P11229 1/20 0.50
TBXA2R P21731 1/20 0.50
GGT1 P19440 1/20 0.48
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 4/20 0.43
ARG1 P05089 1/20 0.43
ARG2 P78540 1/20 0.43
TDP1 Q9NUW8 2/20 0.42
FFAR1 O14842 1/20 0.42
CPT2 P23786 1/20 0.42
BLM P54132 2/20 0.42
MEN1 O00255 2/20 0.38
CYP1A2 P05177 2/20 0.38
KMT2A Q03164 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL162455 1.00 TSHR (0.55) TSHRCYP2C19HIF1ACYP2D6ADRA1A
SCHEMBL1875520 1.00 TSHR (0.55) TSHRCYP2C19HIF1ACYP2D6ADRA1A
Hydrochloric Acid SCHEMBL28641269 0.97 CYP2C19 (0.52) TSHRCYP2C19HIF1ACYP2D6ADRA1A
SCHEMBL2721718 0.85 CYP2C19 (0.41) TSHRCYP2C19HIF1ACYP2D6ADRA1A
Water SCHEMBL18669981 0.82 TSHR (0.39) TSHRCYP2C19HIF1ACYP2D6ADRA1A
Phenol SCHEMBL28180129 0.82 BLM (0.56) TSHRCYP2C19HIF1ACYP2D6ADRA1A
SCHEMBL161723 0.81 GGT1 (0.46) TSHRCYP2C19HIF1ACYP2D6ADRA1A
SCHEMBL161722 0.81 GGT1 (0.46) TSHRCYP2C19HIF1ACYP2D6ADRA1A
SCHEMBL573396 0.81 GGT1 (0.46) TSHRCYP2C19HIF1ACYP2D6ADRA1A
SCHEMBL1986433 0.81 GGT1 (0.46) TSHRCYP2C19HIF1ACYP2D6ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117285626-A Alpha v beta 6 integrin ligand and its application 箭头药业股份有限公司 2023-12-26 CN claimed
CN-116670151-A Antibacterial cyclic peptides targeting acinetobacter and other gram negative pathogens 犹他大学研究基金会 2023-08-29 CN claimed
EP-3288599-B1 WOUND PACKING MATERIAL COMPRISING CHEMOEFFECTOR CHEMOKIND INC (US) 2023-06-07 EP claimed
US-20230105982-A1 INSULIN-INCRETIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2023-04-06 US claimed
US-20220380425-A1 ANGPTL3 BASED VACCINE FOR THE TREATMENT OF LIVER DISEASE CADILA HEALTHCARE LIMITED (IN) 2022-12-01 US claimed
EP-3993820-A1 ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 Cadila Healthcare Limited (IN) 2022-05-11 EP claimed
WO-2021001804-A1 ANGPTL3 BASED VACCINE FOR THE TREATMENT OF LIVER DISEASE CADILA HEALTHCARE LIMITED (IN) 2021-01-07 WO claimed
US-20200399311-A1 NOVEL PEPTIDE BASED PCSK9 VACCINE ZYDUS LIFESCIENCES LIMITED (IN) 2020-12-24 US claimed
EP-3609532-A1 NOVEL PEPTIDE BASED PCSK9 VACCINE Cadila Healthcare Limited (IN) 2020-02-19 EP claimed
CN-110536696-A PCSK9 vaccine based on new peptide CADILA HEALTHCARE LTD 2019-12-03 CN claimed
WO-2017160669-A1 INSULIN-INCRETIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2017-09-21 WO claimed
US-20160318987-A1 PROTEASE RESISTANT PEPTIDES MEDIMMUNE LIMITED (GB) 2016-11-03 US claimed
EP-3080153-A2 PROTEASE RESISTANT PEPTIDES Medimmune Limited (GB) 2016-10-19 EP claimed
WO-2015086686-A2 PROTEASE RESISTANT PEPTIDES MEDIMMUNE LIMITED (GB) 2015-06-18 WO claimed
EP-2644185-A1 THICK CLEANING COMPOSITION Suzhou Yuansuji Chemical Industry Co., Ltd. (CN) 2013-10-02 EP claimed
CN-103338743-A Thick cleaning composition SUZHOU YUANSUJI CHEMICAL INDUSTRY CO LTD 2013-10-02 CN claimed
US-20130251648-A1 THICK CLEANING COMPOSITION SUZHOU YUANSUJI CHEMICAL INDUSTRY CO., LTD. (CN) 2013-09-26 US claimed
US-20120264685-A1 SHORT CHAIN PEPTIDOMIMETICS BASED ORALLY ACTIVE GLP 1 AGONIST AND GLUCAGON RECEPTOR ANTAGONIST CADILA HEALTHCARE LIMITED (IN) 2012-10-18 US claimed
EP-2491054-A2 SHORT CHAIN PEPTIDOMIMETICS BASED ORALLY ACTIVE GLP-1 AGONIST AND GLUCAGON RECEPTOR ANTAGONIST Cadila Healthcare Limited (IN) 2012-08-29 EP claimed
WO-2011048614-A2 SHORT CHAIN PEPTIDOMIMETICS BASED ORALLY ACTIVE GLP-1 AGONIST AND GLUCAGON RECEPTOR ANTAGONIST CADILA HEALTHCARE LIMITED (IN) 2011-04-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230105982-A1 INSULIN-INCRETIN CONJUGATES GIPR, GLP1R, GCGR TSHR 116/4885CYP2C19 4050/4885HIF1A 3920/4885
US-20220380425-A1 ANGPTL3 BASED VACCINE FOR THE TREATMENT OF LIVER DISEASE HDGFL3, PCSK9, TEK TSHR 3468/4885CYP2C19 4723/4885HIF1A 1898/4885
US-20120264685-A1 SHORT CHAIN PEPTIDOMIMETICS BASED ORALLY ACTIVE GLP 1 AGONIST AND GLUCAGON RECEPTOR ANTAGONIST GIPR, GLP1R, DPP4 TSHR 208/4885CYP2C19 199/4885HIF1A 3259/4885
US-20200399311-A1 NOVEL PEPTIDE BASED PCSK9 VACCINE PCSK9, PCSK7, PCSK6 TSHR 2512/4885CYP2C19 3030/4885HIF1A 4577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.